GWS
SUPN icon

Glassman Wealth Services’s Supernus Pharmaceuticals SUPN Stock Holding History

Glassman Wealth Services’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-16
Closed -$441 – 2070
2023
Q3 		$441 Buy
+16
New +$487 ﹤0.01% 1762
2019
Q4 		– Sell
-40
Closed -$1K – 1470
2019
Q3 		$1K Buy
+40
New +$1.19K ﹤0.01% 920
2019
Q2 		– Sell
-34
Closed -$1K – 1350
2019
Q1 		$1K Buy
34
+26
+325% +$967 ﹤0.01% 893
2018
Q4 		$0 Hold
8
– – ﹤0.01% 974
2018
Q3 		$0 Hold
8
– – ﹤0.01% 955
2018
Q2 		$0 Hold
8
– – ﹤0.01% 951
2018
Q1 		$0 Buy
+8
New +$334 ﹤0.01% 914

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Glassman Wealth Services's SUPN Position: Q4 2023 in Review

Glassman Wealth Services sold out of Supernus Pharmaceuticals (SUPN) in Q4 2023, closing a stake of 16 shares — an estimated $441 sold.

Glassman Wealth Services first reported a position in SUPN in Q1 2018 and held it in 7 quarters. The position peaked at $1K in Q3 2019. 246 funds tracked by Wall St. Rank hold SUPN as of Q4 2023.

  • Glassman Wealth Services reported no remaining Supernus Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Glassman Wealth Services sold 16 Supernus Pharmaceuticals shares in Q4 2023, an estimated $441.
  • Glassman Wealth Services first reported a position in Supernus Pharmaceuticals in Q1 2018 and held it in 7 quarters.
  • Glassman Wealth Services's Supernus Pharmaceuticals position peaked at $1K in Q3 2019.
  • 246 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2023.

Based on Glassman Wealth Services's 13F filing for Q4 2023, filed 12 Feb 2024.